Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline RAHWAY ...

Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this ...

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in billions of dollars to the ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) blockbuster anti-PD-1 therapy Keytruda in a late-stage trial ...

Ivonescimab slashed the risk of disease progression or death by a whopping 49% compared with Merck’s Keytruda in the phase 3 HARMONi-2 study that Akeso is conducting in Chinese patients with ...